United Immunity

Executive Summary

United Immunity is a Japanese biotech company pioneering myeloid cell-targeted drug delivery using its Myeloid Targeting Platform™. The platform utilizes pullulan-based nanoparticles (PNP and P-LNP) to selectively deliver therapeutic payloads to macrophages and dendritic cells via the DC-SIGN receptor. This approach has broad potential across oncology, infectious diseases, autoimmune disorders, fibrosis, and metabolic diseases, addressing significant unmet medical needs. The company has raised ¥11 billion (~$100M) and advanced to Phase 1 clinical development. Its lead programs focus on oncology and immunotherapy, with upcoming catalysts including Phase 1 data readouts and expansion into new indications. With strong IP and a seasoned team, United Immunity is positioned to become a leader in myeloid cell-targeted therapies, offering novel treatment options for diseases with high morbidity.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Data Readout in Oncology80% success
• 2027Initiation of Phase 2 Trial60% success
• TBDStrategic Partnership or Licensing Deal50% success